{"id":67887,"date":"2026-06-10T14:52:46","date_gmt":"2026-06-10T06:52:46","guid":{"rendered":"https:\/\/flcube.com\/?p=67887"},"modified":"2026-06-10T14:52:47","modified_gmt":"2026-06-10T06:52:47","slug":"lynk-pharmaceuticals-and-formation-bio-dose-first-patient-in-phase-i-blkr201-study-for-cns-penetrant-tyk201-inhibitor-backed-by-605m-partnership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67887","title":{"rendered":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lynk Pharmaceuticals Co., Ltd.<\/strong> and its U.S. partner <strong>Formation Bio<\/strong> announced the dosing of the first patient in the <strong>Phase I BLKR201 clinical study<\/strong> evaluating their investigational compound <strong>BLKR201\/LNK01006<\/strong>, a <strong>novel, selective, CNS-penetrant allosteric inhibitor of TYK2<\/strong> designed to modulate immune signaling within the central nervous system.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Phase I trial is a <strong>single ascending dose (SAD) and multiple ascending dose (MAD)<\/strong> study conducted in healthy subjects, with top-line data expected in <strong>early 2027<\/strong>. BLKR201\/LNK01006 demonstrates <strong>favorable CNS exposure and high target selectivity<\/strong>, positioning it as a potential therapeutic candidate for <strong>neurological autoimmune and inflammatory diseases<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-clinical-development-program\" class=\"wp-block-heading\">Clinical Development Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Study Component<\/th><th>Design<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Phase I SAD\/MAD<\/td><td>Ongoing<\/td><\/tr><tr><td><strong>Population<\/strong><\/td><td>Healthy volunteers<\/td><td>Enrolling<\/td><\/tr><tr><td><strong>Primary Objectives<\/strong><\/td><td>Safety, tolerability, PK\/PD<\/td><td>Early 2027 readout<\/td><\/tr><tr><td><strong>Secondary Objectives<\/strong><\/td><td>CNS penetration, target engagement<\/td><td>Early 2027 readout<\/td><\/tr><tr><td><strong>Geographic Scope<\/strong><\/td><td>International collaboration<\/td><td>U.S.-China partnership<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-platform-amp-therapeutic-potential\" class=\"wp-block-heading\">Technology Platform &amp; Therapeutic Potential<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism<\/strong>: Allosteric TYK2 inhibition with CNS penetration capability<\/li>\n\n\n\n<li><strong>Selectivity<\/strong>: High target specificity minimizing off-target effects<\/li>\n\n\n\n<li><strong>CNS Exposure<\/strong>: Favorable blood-brain barrier penetration profile<\/li>\n\n\n\n<li><strong>Therapeutic Areas<\/strong>:<\/li>\n\n\n\n<li>Multiple sclerosis<\/li>\n\n\n\n<li>Neuromyelitis optica spectrum disorders (NMOSD)<\/li>\n\n\n\n<li>Other neuroinflammatory conditions<\/li>\n\n\n\n<li>Autoimmune encephalitis<\/li>\n\n\n\n<li><strong>Competitive Advantage<\/strong>: Addresses unmet need for targeted immunomodulation within the central nervous system<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-partnership-amp-financial-structure\" class=\"wp-block-heading\">Strategic Partnership &amp; Financial Structure<\/h2>\n\n\n\n<h3 id=\"h-december-2025-licensing-agreement-with-bleecker-bio\" class=\"wp-block-heading\">December 2025 Licensing Agreement with Bleecker Bio<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Partner<\/strong>: Bleecker Bio (subsidiary of Formation Bio)<\/li>\n\n\n\n<li><strong>Territory<\/strong>: Outside Greater China (Mainland China, Hong Kong, Macau, Taiwan retained by Lynk)<\/li>\n\n\n\n<li><strong>Upfront Consideration<\/strong>: Cash payment plus minority equity stake in Bleecker Bio<\/li>\n\n\n\n<li><strong>Milestone Payments<\/strong>: Up to <strong>USD 605 million<\/strong> across development, regulatory, and commercial milestones<\/li>\n\n\n\n<li><strong>Royalty Structure<\/strong>: Tiered royalties on future net sales in licensed territories<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-territory-allocation\" class=\"wp-block-heading\">Territory Allocation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lynk Pharmaceuticals<\/strong>: Retains full rights in Greater China<\/li>\n\n\n\n<li><strong>Bleecker Bio\/Formation Bio<\/strong>: Exclusive global rights excluding Greater China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-landscape\" class=\"wp-block-heading\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TYK2 Inhibitor Market<\/strong>: Emerging class with demonstrated success in peripheral autoimmune diseases<\/li>\n\n\n\n<li><strong>CNS Penetration Challenge<\/strong>: Most existing TYK2 inhibitors lack adequate brain exposure<\/li>\n\n\n\n<li><strong>Neurological Autoimmune Burden<\/strong>: Affects millions globally with limited targeted therapeutic options<\/li>\n\n\n\n<li><strong>Pipeline Validation<\/strong>: Partnership structure reflects strong confidence in asset potential<\/li>\n\n\n\n<li><strong>Financial Impact<\/strong>: Non-dilutive funding enables Lynk to advance multiple pipeline programs<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This first-in-human study represents a critical milestone in developing the first CNS-penetrant TYK2 inhibitor, potentially opening new treatment paradigms for neurological autoimmune conditions that have historically been difficult to address with systemic immunomodulators.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development timelines, regulatory pathways, partnership obligations, and financial expectations. Actual results may differ due to clinical, regulatory, and commercial risks inherent in drug development.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4176,1351],"class_list":["post-67887","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-formation-bio","tag-lynk-pharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67887\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership\" \/>\n<meta property=\"og:description\" content=\"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67887\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-10T06:52:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T06:52:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership\",\"datePublished\":\"2026-06-10T06:52:46+00:00\",\"dateModified\":\"2026-06-10T06:52:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887\"},\"wordCount\":430,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Formation Bio\",\"Lynk Pharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67887#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67887\",\"name\":\"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-10T06:52:46+00:00\",\"dateModified\":\"2026-06-10T06:52:47+00:00\",\"description\":\"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\\\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67887\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67887#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership - Insight, China&#039;s Pharmaceutical Industry","description":"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67887","og_locale":"en_US","og_type":"article","og_title":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership","og_description":"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.","og_url":"https:\/\/flcube.com\/?p=67887","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-10T06:52:46+00:00","article_modified_time":"2026-06-10T06:52:47+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67887#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67887"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership","datePublished":"2026-06-10T06:52:46+00:00","dateModified":"2026-06-10T06:52:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67887"},"wordCount":430,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Formation Bio","Lynk Pharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67887#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67887","url":"https:\/\/flcube.com\/?p=67887","name":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-10T06:52:46+00:00","dateModified":"2026-06-10T06:52:47+00:00","description":"Lynk Pharmaceuticals Co., Ltd. and its U.S. partner Formation Bio announced the dosing of the first patient in the Phase I BLKR201 clinical study evaluating their investigational compound BLKR201\/LNK01006, a novel, selective, CNS-penetrant allosteric inhibitor of TYK2 designed to modulate immune signaling within the central nervous system.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67887#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67887"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67887#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lynk Pharmaceuticals and Formation Bio Dose First Patient in Phase I BLKR201 Study for CNS-Penetrant TYK201 Inhibitor, Backed by $605M Partnership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67887","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67887"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67887\/revisions"}],"predecessor-version":[{"id":67888,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67887\/revisions\/67888"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67887"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67887"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67887"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}